{"id":9819,"date":"2026-06-27T11:39:59","date_gmt":"2026-06-27T15:39:59","guid":{"rendered":"https:\/\/news.ftcpublications.com\/core\/?p=9819"},"modified":"2026-06-27T11:40:03","modified_gmt":"2026-06-27T15:40:03","slug":"gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments","status":"publish","type":"post","link":"https:\/\/news.ftcpublications.com\/core\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\/","title":{"rendered":"Gene-editing therapy shows durable success in common cholesterol disorder, paving way for one-shot treatments"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Gene-editing therapies are delivering sustained cholesterol reductions in early trials for a common lipid disorder. The approach targets liver genes that regulate LDL cholesterol, offering potential one-time treatment. These results signal a shift toward durable cardiovascular prevention with simplified care.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Researchers view these findings as a milestone for cardiometabolic medicine. They also highlight important questions about safety, access, and long-term monitoring. Together, these threads define the next chapter for precision heart disease prevention.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The burden of LDL cholesterol disorders<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Elevated LDL cholesterol drives atherosclerotic cardiovascular disease worldwide. Even modest reductions in LDL lower heart attack and stroke risk. Many people, however, struggle to maintain long-term control with daily or intermittent therapies.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Heterozygous familial hypercholesterolemia is a common inherited condition. It affects about one in 250 people globally. Patients face lifelong exposure to high LDL and accelerated atherosclerosis without effective, sustained treatment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Conventional regimens reduce risk yet require ongoing adherence. Some patients cannot tolerate high-intensity statins or reach guideline targets. These gaps fuel interest in durable therapies that work with a single intervention.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Targeting PCSK9 and ANGPTL3 in the liver<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Scientists have focused on liver genes that control lipoprotein metabolism. PCSK9 raises LDL levels by promoting LDL receptor degradation. ANGPTL3 modulates triglycerides and LDL through lipase activity regulation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Monoclonal antibodies against PCSK9 transform LDL management with potent reductions. Small interfering RNA also silences PCSK9 with infrequent dosing. Yet these options still require repeat administrations over years.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Gene editing aims to permanently inactivate these targets in hepatocytes. A single session could create lasting suppression of PCSK9 or ANGPTL3. This strategy could simplify care and improve lifetime risk reduction.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How one-shot gene editing works<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Most programs deliver gene editors to the liver using lipid nanoparticles. These particles carry guide RNAs and editor instructions as mRNA. Hepatocytes translate the editor and perform the targeted DNA change.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Several teams use base editing to avoid double-strand DNA breaks. Adenine base editors can introduce a single-letter change that disables PCSK9. This precise approach reduces the chance of large insertions or deletions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Other approaches use CRISPR nucleases or prime editors with different capabilities. The common objective remains sustained target inactivation in liver cells. Successful editing effectively mimics protective human loss-of-function variants.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Transience of editor expression is a key safety feature. The editor degrades after a short window of activity. The desired genetic change, however, persists in the edited hepatocytes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Early clinical results show durable LDL reductions<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">First-in-human studies have enrolled adults with high cardiovascular risk. Many participants had heterozygous familial hypercholesterolemia or established atherosclerotic disease. They often remained on background lipid-lowering therapy during follow-up.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Initial cohorts received single doses with careful dose escalation. Investigators measured circulating PCSK9, LDL cholesterol, and safety markers. They also monitored editing durability over months after treatment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Reports describe substantial LDL reductions after one infusion. Several participants achieved reductions around 40% to 60% versus baseline. PCSK9 protein levels dropped markedly, indicating strong target engagement.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Follow-up suggests durable effects beyond six months in early cohorts. Some participants maintained large LDL reductions at one year. These findings support the concept of a one-shot therapy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Investigators continue to collect multi-year data to confirm persistence. They are also exploring optimized doses for broader populations. These refinements could strengthen benefit consistency across diverse patients.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Safety profile and remaining uncertainties<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Safety remains central for a permanent gene-based therapy. Most reported adverse events were mild and transient thus far. Common effects included infusion reactions and temporary liver enzyme elevations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Early programs reported serious cardiovascular events in isolated cases. Participants had high underlying risk and advanced disease. Investigators assessed causality carefully while refining dosing and eligibility criteria.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Genomic safety requires ongoing scrutiny beyond clinical events. Teams screen for off-target edits using sensitive assays. They also monitor on-target byproducts like unintended insertions or deletions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Long-term surveillance frameworks are therefore essential. Registries and extended follow-up can detect rare late effects. Post-authorization commitments will likely include decade-long monitoring plans.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Why durability matters for patients<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Many people miss pills or injections over time. Nonadherence weakens the proven benefits of LDL reduction. A one-time treatment could minimize this adherence gap substantially.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Durable control also supports earlier intervention strategies. Clinicians could treat high-risk patients soon after diagnosis. Early, sustained LDL lowering yields cumulative cardiovascular benefit across decades.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For familial hypercholesterolemia, lifelong burden begins in childhood. Adult interventions still meaningfully reduce risk in these patients. Durable gene editing could extend that benefit horizon even further.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Comparisons with existing therapies<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Statins remain foundational due to outcomes data and affordability. Ezetimibe provides an additional oral option with modest LDL reductions. PCSK9 antibodies and siRNA deliver potent, predictable lowering with infrequent dosing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Gene editing could match potency while eliminating repeated administrations. The tradeoff includes higher upfront risk concentration and irreversible changes. Careful patient selection and consent therefore remain critical.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Head-to-head trials will help clarify relative value. They can compare LDL trajectories, safety, and clinical outcomes. Real-world evidence will further inform practice and coverage decisions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Implications for health systems and access<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">One-time therapies challenge traditional payment models. Payers often prefer costs spread across years of treatment. Gene editing concentrates cost in a single episode of care.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">New contracts may link payment to durability of effect. Outcomes-based arrangements could align incentives across stakeholders. Transparent follow-up data will underpin these value frameworks.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Equitable access must guide deployment strategies. Health systems should prioritize high-risk patients using clear criteria. Outreach programs can reduce disparities in familial hypercholesterolemia diagnosis and care.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Regulatory and ethical considerations<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Regulators emphasize robust safety characterization and manufacturing consistency. Chemistry, manufacturing, and controls need stringent validation steps. Lot-to-lot reproducibility is vital for confident scaling.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ethically, these therapies involve somatic editing only. They do not affect germline cells or descendants. Nonetheless, informed consent must address irreversibility and lingering uncertainties.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Special populations require tailored guidance. Pregnancy, severe liver disease, and pediatric use need careful evaluation. Long-term contraception recommendations may apply around the treatment window.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Manufacturing and delivery advances<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Lipid nanoparticles continue to improve in targeting and tolerability. Formulations enhance hepatocyte uptake while limiting systemic exposure. Process innovations also boost batch consistency and scalability.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Guide design algorithms now better predict off-target risks. Improved editors reduce bystander edits and unwanted conversions. These refinements support safer dose selection and broader eligibility.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Analytical methods are advancing alongside manufacturing. Deep sequencing enables sensitive detection of rare edits. Standardized assays will facilitate cross-trial comparisons and regulatory review.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Next steps and milestones to watch<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Larger Phase 2 studies will test consistency across diverse patients. Investigators will refine dose ranges and infusion protocols. They will also track lipid changes over longer horizons.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Combination strategies may unlock additional benefits. Editing ANGPTL3 could complement PCSK9 suppression in mixed dyslipidemia. Carefully designed trials can assess additive risk reduction.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Outcomes studies remain the ultimate benchmark. LDL reduction provides a strong surrogate endpoint today. Event-driven trials will confirm impacts on heart attacks and strokes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What patients and clinicians should consider now<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Today\u2019s care still relies on established therapies and lifestyle changes. Clinicians should optimize statins, ezetimibe, and PCSK9 agents when indicated. Shared decision-making can address preferences and adherence challenges.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Referral pathways for familial hypercholesterolemia remain crucial. Cascade screening can identify affected relatives early. Genetic counseling supports informed choices about future interventions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Clinical trials offer access to cutting-edge options with oversight. Eligible patients can contribute to evidence while receiving close monitoring. Trial participation accelerates progress for the broader community.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Outlook for one-shot cholesterol treatments<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Gene editing has crossed a meaningful threshold in lipid medicine. Early data show durable target engagement and potent LDL lowering. Safety signals appear manageable with careful selection and dosing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The field still owes society long-term clarity on risks. Transparent data sharing and registries will build collective confidence. Regulatory guidance will evolve as evidence matures across programs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">If durability persists over years, care models could transform. Patients might receive a single infusion and resume normal life. Clinics could redeploy resources from chronic administration to prevention outreach.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The promise of one-shot therapy feels closer than ever. Success requires rigorous science, ethical stewardship, and equitable access. With these pillars, durable gene editing could redefine cardiovascular prevention worldwide.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gene-editing therapies are delivering sustained cholesterol reductions in early trials for a common lipid disorder. The approach targets liver genes that regulate LDL cholesterol, offering potential one-time treatment. These results signal a shift toward durable cardiovascular prevention with simplified care. Researchers view these findings as a milestone for cardiometabolic medicine. They also highlight important questions [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":9820,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"apple_news_api_created_at":"2026-06-27T15:40:04Z","apple_news_api_id":"e4dcd6df-e071-4a6d-ab7c-bcacc5646f18","apple_news_api_modified_at":"2026-06-27T15:40:04Z","apple_news_api_revision":"AAAAAAAAAAD\/\/\/\/\/\/\/\/\/\/w==","apple_news_api_share_url":"https:\/\/apple.news\/A5NzW3-BxSm2rfLysxWRvGA","apple_news_cover_media_provider":"image","apple_news_coverimage":0,"apple_news_coverimage_caption":"","apple_news_cover_video_id":0,"apple_news_cover_video_url":"","apple_news_cover_embedwebvideo_url":"","apple_news_is_hidden":"","apple_news_is_paid":"","apple_news_is_preview":"","apple_news_is_sponsored":"","apple_news_maturity_rating":"","apple_news_metadata":"\"\"","apple_news_pullquote":"","apple_news_pullquote_position":"","apple_news_slug":"","apple_news_sections":[],"apple_news_suppress_video_url":false,"apple_news_use_image_component":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[1],"tags":[],"ppma_author":[356],"class_list":["post-9819","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"apple_news_notices":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gene-editing therapy shows durable success in common cholesterol disorder, paving way for one-shot treatments<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/news.ftcpublications.com\/core\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gene-editing therapy shows durable success in common cholesterol disorder, paving way for one-shot treatments\" \/>\n<meta property=\"og:description\" content=\"Gene-editing therapies are delivering sustained cholesterol reductions in early trials for a common lipid disorder. The approach targets liver genes that regulate LDL cholesterol, offering potential one-time treatment. These results signal a shift toward durable cardiovascular prevention with simplified care. Researchers view these findings as a milestone for cardiometabolic medicine. They also highlight important questions [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/news.ftcpublications.com\/core\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\/\" \/>\n<meta property=\"og:site_name\" content=\"FTC Publications Newswire\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ftcpublications\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-27T15:39:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-27T15:40:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/news.ftcpublications.com\/core\/wp-content\/uploads\/GgdjETyftpoRCp5Hq9Xz3_7lDdLw4Z.jpg.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1376\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"FTC Publications\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"FTC Publications\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\\\/\"},\"author\":{\"name\":\"FTC Publications\",\"@id\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/#\\\/schema\\\/person\\\/7a8664b6153a734ceddf3151bd941270\"},\"headline\":\"Gene-editing therapy shows durable success in common cholesterol disorder, paving way for one-shot treatments\",\"datePublished\":\"2026-06-27T15:39:59+00:00\",\"dateModified\":\"2026-06-27T15:40:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\\\/\"},\"wordCount\":1339,\"publisher\":{\"@id\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/wp-content\\\/uploads\\\/GgdjETyftpoRCp5Hq9Xz3_7lDdLw4Z.jpg.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\\\/\",\"url\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\\\/\",\"name\":\"Gene-editing therapy shows durable success in common cholesterol disorder, paving way for one-shot treatments\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/wp-content\\\/uploads\\\/GgdjETyftpoRCp5Hq9Xz3_7lDdLw4Z.jpg.jpg\",\"datePublished\":\"2026-06-27T15:39:59+00:00\",\"dateModified\":\"2026-06-27T15:40:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\\\/#primaryimage\",\"url\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/wp-content\\\/uploads\\\/GgdjETyftpoRCp5Hq9Xz3_7lDdLw4Z.jpg.jpg\",\"contentUrl\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/wp-content\\\/uploads\\\/GgdjETyftpoRCp5Hq9Xz3_7lDdLw4Z.jpg.jpg\",\"width\":1376,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gene-editing therapy shows durable success in common cholesterol disorder, paving way for one-shot treatments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/#website\",\"url\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/\",\"name\":\"FTC Publications Newswire\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/#organization\",\"name\":\"FTC Publications News\",\"url\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/wp-content\\\/uploads\\\/2016\\\/09\\\/2014-FTC-TextOnly-Logo-Square.png\",\"contentUrl\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/wp-content\\\/uploads\\\/2016\\\/09\\\/2014-FTC-TextOnly-Logo-Square.png\",\"width\":460,\"height\":460,\"caption\":\"FTC Publications News\"},\"image\":{\"@id\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ftcpublications\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ftc-publications-inc-\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/#\\\/schema\\\/person\\\/7a8664b6153a734ceddf3151bd941270\",\"name\":\"FTC Publications\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7442f1cf75aa91d0ffc9e9862fd31ab173bfeece2402296357881bfebd0d627e?s=96&d=mm&r=gb1739aeddd6a3f95081b6cb498d90525\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7442f1cf75aa91d0ffc9e9862fd31ab173bfeece2402296357881bfebd0d627e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7442f1cf75aa91d0ffc9e9862fd31ab173bfeece2402296357881bfebd0d627e?s=96&d=mm&r=g\",\"caption\":\"FTC Publications\"},\"description\":\"Bylines from \\\"FTC Publications\\\" are created typically via a collection of writers from the agency in general.\",\"url\":\"https:\\\/\\\/news.ftcpublications.com\\\/core\\\/author\\\/ftcpublications\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gene-editing therapy shows durable success in common cholesterol disorder, paving way for one-shot treatments","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/news.ftcpublications.com\/core\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\/","og_locale":"en_US","og_type":"article","og_title":"Gene-editing therapy shows durable success in common cholesterol disorder, paving way for one-shot treatments","og_description":"Gene-editing therapies are delivering sustained cholesterol reductions in early trials for a common lipid disorder. The approach targets liver genes that regulate LDL cholesterol, offering potential one-time treatment. These results signal a shift toward durable cardiovascular prevention with simplified care. Researchers view these findings as a milestone for cardiometabolic medicine. They also highlight important questions [&hellip;]","og_url":"https:\/\/news.ftcpublications.com\/core\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\/","og_site_name":"FTC Publications Newswire","article_publisher":"https:\/\/www.facebook.com\/ftcpublications","article_published_time":"2026-06-27T15:39:59+00:00","article_modified_time":"2026-06-27T15:40:03+00:00","og_image":[{"width":1376,"height":768,"url":"https:\/\/news.ftcpublications.com\/core\/wp-content\/uploads\/GgdjETyftpoRCp5Hq9Xz3_7lDdLw4Z.jpg.jpg","type":"image\/jpeg"}],"author":"FTC Publications","twitter_card":"summary_large_image","twitter_misc":{"Written by":"FTC Publications","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/news.ftcpublications.com\/core\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\/#article","isPartOf":{"@id":"https:\/\/news.ftcpublications.com\/core\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\/"},"author":{"name":"FTC Publications","@id":"https:\/\/news.ftcpublications.com\/core\/#\/schema\/person\/7a8664b6153a734ceddf3151bd941270"},"headline":"Gene-editing therapy shows durable success in common cholesterol disorder, paving way for one-shot treatments","datePublished":"2026-06-27T15:39:59+00:00","dateModified":"2026-06-27T15:40:03+00:00","mainEntityOfPage":{"@id":"https:\/\/news.ftcpublications.com\/core\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\/"},"wordCount":1339,"publisher":{"@id":"https:\/\/news.ftcpublications.com\/core\/#organization"},"image":{"@id":"https:\/\/news.ftcpublications.com\/core\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\/#primaryimage"},"thumbnailUrl":"https:\/\/news.ftcpublications.com\/core\/wp-content\/uploads\/GgdjETyftpoRCp5Hq9Xz3_7lDdLw4Z.jpg.jpg","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/news.ftcpublications.com\/core\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\/","url":"https:\/\/news.ftcpublications.com\/core\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\/","name":"Gene-editing therapy shows durable success in common cholesterol disorder, paving way for one-shot treatments","isPartOf":{"@id":"https:\/\/news.ftcpublications.com\/core\/#website"},"primaryImageOfPage":{"@id":"https:\/\/news.ftcpublications.com\/core\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\/#primaryimage"},"image":{"@id":"https:\/\/news.ftcpublications.com\/core\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\/#primaryimage"},"thumbnailUrl":"https:\/\/news.ftcpublications.com\/core\/wp-content\/uploads\/GgdjETyftpoRCp5Hq9Xz3_7lDdLw4Z.jpg.jpg","datePublished":"2026-06-27T15:39:59+00:00","dateModified":"2026-06-27T15:40:03+00:00","breadcrumb":{"@id":"https:\/\/news.ftcpublications.com\/core\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/news.ftcpublications.com\/core\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/news.ftcpublications.com\/core\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\/#primaryimage","url":"https:\/\/news.ftcpublications.com\/core\/wp-content\/uploads\/GgdjETyftpoRCp5Hq9Xz3_7lDdLw4Z.jpg.jpg","contentUrl":"https:\/\/news.ftcpublications.com\/core\/wp-content\/uploads\/GgdjETyftpoRCp5Hq9Xz3_7lDdLw4Z.jpg.jpg","width":1376,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/news.ftcpublications.com\/core\/gene-editing-therapy-shows-durable-success-in-common-cholesterol-disorder-paving-way-for-one-shot-treatments\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/news.ftcpublications.com\/core\/"},{"@type":"ListItem","position":2,"name":"Gene-editing therapy shows durable success in common cholesterol disorder, paving way for one-shot treatments"}]},{"@type":"WebSite","@id":"https:\/\/news.ftcpublications.com\/core\/#website","url":"https:\/\/news.ftcpublications.com\/core\/","name":"FTC Publications Newswire","description":"","publisher":{"@id":"https:\/\/news.ftcpublications.com\/core\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/news.ftcpublications.com\/core\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/news.ftcpublications.com\/core\/#organization","name":"FTC Publications News","url":"https:\/\/news.ftcpublications.com\/core\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/news.ftcpublications.com\/core\/#\/schema\/logo\/image\/","url":"https:\/\/news.ftcpublications.com\/core\/wp-content\/uploads\/2016\/09\/2014-FTC-TextOnly-Logo-Square.png","contentUrl":"https:\/\/news.ftcpublications.com\/core\/wp-content\/uploads\/2016\/09\/2014-FTC-TextOnly-Logo-Square.png","width":460,"height":460,"caption":"FTC Publications News"},"image":{"@id":"https:\/\/news.ftcpublications.com\/core\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ftcpublications","https:\/\/www.linkedin.com\/company\/ftc-publications-inc-\/"]},{"@type":"Person","@id":"https:\/\/news.ftcpublications.com\/core\/#\/schema\/person\/7a8664b6153a734ceddf3151bd941270","name":"FTC Publications","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7442f1cf75aa91d0ffc9e9862fd31ab173bfeece2402296357881bfebd0d627e?s=96&d=mm&r=gb1739aeddd6a3f95081b6cb498d90525","url":"https:\/\/secure.gravatar.com\/avatar\/7442f1cf75aa91d0ffc9e9862fd31ab173bfeece2402296357881bfebd0d627e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7442f1cf75aa91d0ffc9e9862fd31ab173bfeece2402296357881bfebd0d627e?s=96&d=mm&r=g","caption":"FTC Publications"},"description":"Bylines from \"FTC Publications\" are created typically via a collection of writers from the agency in general.","url":"https:\/\/news.ftcpublications.com\/core\/author\/ftcpublications\/"}]}},"jetpack_featured_media_url":"https:\/\/news.ftcpublications.com\/core\/wp-content\/uploads\/GgdjETyftpoRCp5Hq9Xz3_7lDdLw4Z.jpg.jpg","jetpack_shortlink":"https:\/\/wp.me\/paaAgn-2yn","jetpack-related-posts":[{"id":7836,"url":"https:\/\/news.ftcpublications.com\/core\/single-dose-crispr-therapy-slashes-ldl-cholesterol-in-first-human-data-signaling-a-potential-shift-in-heart-disease-treatment\/","url_meta":{"origin":9819,"position":0},"title":"Single-dose CRISPR therapy slashes LDL cholesterol in first human data, signaling a potential shift in heart disease treatment","author":"FTC Publications","date":"November 29, 2025","format":false,"excerpt":"Single-dose CRISPR therapy slashes LDL cholesterol, signaling a potential shift in heart disease treatment Early human data show that a one-time CRISPR-based therapy can markedly lower LDL cholesterol. Investigators reported substantial, durable LDL reductions after a single infusion targeting the PCSK9 gene in the liver. The results suggest a new\u2026","rel":"","context":"In &quot;News&quot;","block_context":{"text":"News","link":"https:\/\/news.ftcpublications.com\/core\/category\/news\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/IHNV8kzzPScE_Bffqg9ej_e752f6263957481e988082a8c3bc45b5.jpg-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/IHNV8kzzPScE_Bffqg9ej_e752f6263957481e988082a8c3bc45b5.jpg-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/IHNV8kzzPScE_Bffqg9ej_e752f6263957481e988082a8c3bc45b5.jpg-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/IHNV8kzzPScE_Bffqg9ej_e752f6263957481e988082a8c3bc45b5.jpg-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/IHNV8kzzPScE_Bffqg9ej_e752f6263957481e988082a8c3bc45b5.jpg-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/IHNV8kzzPScE_Bffqg9ej_e752f6263957481e988082a8c3bc45b5.jpg-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":900,"url":"https:\/\/news.ftcpublications.com\/core\/reduce-your-risk-of-another-heart-attack-or-stroke\/","url_meta":{"origin":9819,"position":1},"title":"Reduce Your Risk of Another Heart Attack or Stroke","author":"FTC Publications","date":"May 14, 2020","format":false,"excerpt":"COVID-19 pandemic highlights importance of maintaining healthy routines After a heart attack or stroke, as many as 1 in 4 survivors will have another one. However, lifestyle changes and working closely with your doctor to manage your health may minimize the risk of a repeat event. Sticking to secondary prevention\u2026","rel":"","context":"In &quot;Entertainment&quot;","block_context":{"text":"Entertainment","link":"https:\/\/news.ftcpublications.com\/core\/category\/entertainment\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/15098.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/15098.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/15098.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/15098.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/15098.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/15098.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":6422,"url":"https:\/\/news.ftcpublications.com\/core\/advances-in-gene-editing-unlock-potential-for-disease-resistant-crops\/","url_meta":{"origin":9819,"position":2},"title":"Advances in gene editing unlock potential for disease-resistant crops","author":"Warith Niallah","date":"July 30, 2025","format":false,"excerpt":"Gene editing technology is transforming agriculture in remarkable ways. Modern methods now allow scientists to create disease-resistant crops with unprecedented precision. This shift offers hope to farmers facing major threats from plant pathogens. Improved crop resilience supports food security and reduces reliance on chemical pesticides. The Need for Disease-Resistant Crops\u2026","rel":"","context":"In &quot;News&quot;","block_context":{"text":"News","link":"https:\/\/news.ftcpublications.com\/core\/category\/news\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/AqirKuFnrm5EuKJLKtxTu_b014eb3f9bb948c68135f8f5c8739f3d.jpg-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/AqirKuFnrm5EuKJLKtxTu_b014eb3f9bb948c68135f8f5c8739f3d.jpg-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/AqirKuFnrm5EuKJLKtxTu_b014eb3f9bb948c68135f8f5c8739f3d.jpg-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/AqirKuFnrm5EuKJLKtxTu_b014eb3f9bb948c68135f8f5c8739f3d.jpg-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/AqirKuFnrm5EuKJLKtxTu_b014eb3f9bb948c68135f8f5c8739f3d.jpg-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/AqirKuFnrm5EuKJLKtxTu_b014eb3f9bb948c68135f8f5c8739f3d.jpg-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":154,"url":"https:\/\/news.ftcpublications.com\/core\/african-americans-at-higher-risk-for-strok\/","url_meta":{"origin":9819,"position":3},"title":"African-Americans at Higher Risk for Stroke","author":"FTC Publications","date":"August 7, 2017","format":false,"excerpt":"Each year, more than 780,000 Americans suffer a stroke. It is the third leading cause of death and a leading cause of long-term disability in the United States. African-Americans suffer more severe strokes than white Americans, and tend to have a higher rate of risk factors such as high blood\u2026","rel":"","context":"In &quot;News&quot;","block_context":{"text":"News","link":"https:\/\/news.ftcpublications.com\/core\/category\/news\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/2017\/08\/image1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/2017\/08\/image1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/2017\/08\/image1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/2017\/08\/image1.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/2017\/08\/image1.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/2017\/08\/image1.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":9256,"url":"https:\/\/news.ftcpublications.com\/core\/new-study-links-microplastics-found-in-human-blood-to-higher-cardiovascular-risk-prompting-calls-for-stricter-plastic-pollution-controls\/","url_meta":{"origin":9819,"position":4},"title":"New study links microplastics found in human blood to higher cardiovascular risk, prompting calls for stricter plastic pollution controls","author":"FTC Publications","date":"April 17, 2026","format":false,"excerpt":"A new peer-reviewed study links microplastics detected in human blood to elevated cardiovascular risk. The findings add urgency to debates over plastic pollution controls worldwide. Researchers also report microplastics lodged in arterial plaques associated with future cardiac events. Together, these results sharpen a growing scientific picture. Policymakers now face intensified\u2026","rel":"","context":"In &quot;News&quot;","block_context":{"text":"News","link":"https:\/\/news.ftcpublications.com\/core\/category\/news\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/FuTpt2YgGubnany4ajIjH_EdRk36z5.jpg.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/FuTpt2YgGubnany4ajIjH_EdRk36z5.jpg.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/FuTpt2YgGubnany4ajIjH_EdRk36z5.jpg.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/FuTpt2YgGubnany4ajIjH_EdRk36z5.jpg.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/FuTpt2YgGubnany4ajIjH_EdRk36z5.jpg.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":7991,"url":"https:\/\/news.ftcpublications.com\/core\/gene-editing-therapy-shows-promising-early-results-reversing-inherited-blindness-in-first-human-trials\/","url_meta":{"origin":9819,"position":5},"title":"Gene-editing therapy shows promising early results reversing inherited blindness in first human trials","author":"FTC Publications","date":"December 13, 2025","format":false,"excerpt":"Early clinical results suggest gene editing can partially restore vision in people born with inherited retinal blindness. Researchers are testing CRISPR-based therapies that directly correct disease-causing mutations inside retinal cells. Several participants show meaningful gains on standardized vision tests after a single treatment. These findings are preliminary, yet they mark\u2026","rel":"","context":"In &quot;News&quot;","block_context":{"text":"News","link":"https:\/\/news.ftcpublications.com\/core\/category\/news\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/o2MtUAODHVPc7iCYghq5B_5ca0622cb9cb4120916913e325d8c7dd.jpg-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/o2MtUAODHVPc7iCYghq5B_5ca0622cb9cb4120916913e325d8c7dd.jpg-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/o2MtUAODHVPc7iCYghq5B_5ca0622cb9cb4120916913e325d8c7dd.jpg-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/o2MtUAODHVPc7iCYghq5B_5ca0622cb9cb4120916913e325d8c7dd.jpg-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/o2MtUAODHVPc7iCYghq5B_5ca0622cb9cb4120916913e325d8c7dd.jpg-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/news.ftcpublications.com\/core\/wp-content\/uploads\/o2MtUAODHVPc7iCYghq5B_5ca0622cb9cb4120916913e325d8c7dd.jpg-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"authors":[{"term_id":356,"user_id":2,"is_guest":0,"slug":"ftcpublications","display_name":"FTC Publications","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/7442f1cf75aa91d0ffc9e9862fd31ab173bfeece2402296357881bfebd0d627e?s=96&d=mm&r=g","author_category":"","user_url":"","last_name":"","first_name":"","job_title":"","description":"Bylines from \"FTC Publications\" are created typically via a collection of writers from the agency in general."}],"_links":{"self":[{"href":"https:\/\/news.ftcpublications.com\/core\/wp-json\/wp\/v2\/posts\/9819","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/news.ftcpublications.com\/core\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news.ftcpublications.com\/core\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news.ftcpublications.com\/core\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/news.ftcpublications.com\/core\/wp-json\/wp\/v2\/comments?post=9819"}],"version-history":[{"count":2,"href":"https:\/\/news.ftcpublications.com\/core\/wp-json\/wp\/v2\/posts\/9819\/revisions"}],"predecessor-version":[{"id":9827,"href":"https:\/\/news.ftcpublications.com\/core\/wp-json\/wp\/v2\/posts\/9819\/revisions\/9827"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news.ftcpublications.com\/core\/wp-json\/wp\/v2\/media\/9820"}],"wp:attachment":[{"href":"https:\/\/news.ftcpublications.com\/core\/wp-json\/wp\/v2\/media?parent=9819"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news.ftcpublications.com\/core\/wp-json\/wp\/v2\/categories?post=9819"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news.ftcpublications.com\/core\/wp-json\/wp\/v2\/tags?post=9819"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/news.ftcpublications.com\/core\/wp-json\/wp\/v2\/ppma_author?post=9819"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}